Lisa M Rimsza

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7788019/publications.pdf

Version: 2024-02-01

67	6,930	236925	144013
papers	citations	25 h-index	57 g-index

67	67	67	8700
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Assessment of 2-Year Storage Conditions on Protein, RNA, and DNA in Unstained Human Tissue Sections, Including a Novel Multiplex Digital Gene Expression Profiling Method with Implications for Biobanking. Biopreservation and Biobanking, 2022, 20, 473-484.	1.0	2
2	Transcriptional profiles define drug refractory disease in myeloma. EJHaem, 2022, 3, 804-814.	1.0	1
3	Mediastinal B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements. Journal of Hematopathology, 2022, 15, 151-155.	0.4	2
4	A Cyclin D1â€“Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research, 2021, 27, 213-225.	7.0	10
5	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica, 2021, 106, 2682-2693.	3.5	44
6	EBVâ€positive HIVâ€associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. British Journal of Haematology, 2021, 194, 870-878.	2.5	14
7	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. Clinical Cancer Research, 2021, 27, 6039-6053.	7.0	17
8	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients â‰¥65 Years Receiving Bendamustine-Rituximab. Blood, 2021, 138, 3517-3517.	1.4	1
9	Transformation of Follicular Lymphoma into Primary Mediastinal B-Cell Lymphoma-like Large B-Cell Lymphoma. Blood, 2021, 138, 4479-4479.	1.4	0
10	Recommendations for Tissue Microarray Construction and Quality Assurance. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 325-330.	1.2	15
11	Positron Emission Tomographyâ€“Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology, 2020, 38, 3003-3011.	1.6	75
12	Primary Pulmonary B-cell Lymphoma. Seminars in Diagnostic Pathology, 2020, 37, 259-267.	1.5	6
13	Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. Journal of Hematopathology, 2020, 13, 231-238.	0.4	7
14	Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma. NAR Cancer, 2020, 2, zcaa029.	3.1	14
15	Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV. Aids, 2020, 34, 2025-2035.	2.2	2
16	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 2020, 61, 2442-2447.	1.3	1
17	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood, 2020, 135, 274-286.	1.4	81
18	Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica, 2020, 105, 318-321.	3.5	5

#	Article	IF	Citations
19	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	1.4	0
20	Profiling of lymphoma from formalin-fixed paraffin-embedded tissue. Seminars in Hematology, 2019, 56, 46-51.	3.4	4
21	Validation of the <scp>MCL</scp>35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. British Journal of Haematology, 2019, 184, 616-624.	2.5	25
22	Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma. Leukemia and Lymphoma, 2019, 60, 3581-3583.	1.3	4
23	Reproducing the molecular subclassification of peripheral T-cell lymphomaâ€“NOS by immunohistochemistry. Blood, 2019, 134, 2159-2170.	1.4	120
24	Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B cell lymphoma. Journal of Hematopathology, 2019, 12, 3-10.	0.4	14
25	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 48.	6.2	24
26	Enhanced DNA repair and genomic stability identify a novel HIVâ€related diffuse large Bâ€cell lymphoma signature. International Journal of Cancer, 2019, 145, 3078-3088.	5.1	16
27	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances, 2019, 3, 3132-3135.	5.2	18
28	Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood, 2019, 133, 81-93.	1.4	34
29	Over-Expression of Transferrin Receptor (TFRC/CD71) and Low Expression of Innate and Adaptive Immune Cell Subsets in HIV-Associated, GCB-DLBCL By Digital Gene Expression Profiling. Blood, 2019, 134, 2783-2783.	1.4	2
30	Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. Blood, 2019, 134, 2769-2769.	1.4	0
31	Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica, 2018, 103, e151-e153.	3.5	22
32	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of Clinical Oncology, 2018, 36, 697-703.	1.6	68
33	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood, 2018, 132, 2401-2405.	1.4	64
34	Genomics of aggressive B-cell lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 69-74.	2.5	15
35	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood, 2018, 132, 413-422.	1.4	89
36	The <scp>MCL</scp>35 gene expression proliferation assay predicts highâ€risk <scp>MCL</scp> patients in a Norwegian cohort of younger patients given intensive first line therapy. British Journal of Haematology, 2018, 183, 225-234.	2.5	24

#	Article	IF	Citations
37	Dissecting aggressive B-cell lymphoma through genomic analysis â€“ What is clinically relevant?. Best Practice and Research in Clinical Haematology, 2018, 31, 187-198.	1.7	2
38	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature, 2018, 560, 387-391.	27.8	276
39	Enhanced DNA Repair and Genomic Stability in HIV(+) Diffuse Large B Cell Lymphoma of Germinal Center Origin. Blood, 2018, 132, 1570-1570.	1.4	0
40	Enhanced Expression of FGF Signaling in Primary Central Nervous System Lymphoma. Blood, 2018, 132, 2847-2847.	1.4	0
41	Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1593-1593.	1.4	0
42	B-cell lymphomas with discordance between pathological features and clinical behavior. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 439-451.	2.8	5
43	The clinicopathologic spectrum of mature aggressive B cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 453-466.	2.8	27
44	Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 467-489.	2.8	59
45	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 113-117.	2.8	5
46	Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition. Journal of Clinical Investigation, 2017, 127, 2365-2377.	8.2	39
47	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. Journal of Clinical Oncology, 2017, 35, 1668-1677.	1.6	102
48	General Biomarker Recommendations for Lymphoma. Journal of the National Cancer Institute, 2016, 108, djw250.	6.3	2
49	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucoseâ€“Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology, 2016, 34, 2020-2027.	1.6	239
50	Langerhans cell histiocytosis shows distinct cytoplasmic expression of major histocompatibility class II antigens. Journal of Hematopathology, 2016, 9, 107-112.	0.4	9
51	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 3035-3035.	1.4	5
52	Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016. Blood, 2016, 128, 616-616.	1.4	3
53	Concurrent Targeting of BCL2 and MYC Transcription Leads to Chemo-Sensitization of Dual-Expressing Diffuse Large B-Cell Lymphoma In Vivo. Blood, 2016, 128, 4090-4090.	1.4	0
54	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2935-2935.	1.4	0

#	Article	IF	Citations
55	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. Blood, 2016, 128, 4651-4651.	1.4	0
56	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Journal of Clinical Oncology, 2015, 33, 2848-2856.	1.6	334
57	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood, 2014, 123, 1214-1217.	1.4	518
58	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. Journal of Clinical Oncology, 2013, 31, 314-320.	1.6	152
59	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOPâ€“Rituximab versus CHOP + 131Iodineâ€”Tositumomab. Clinical Cancer Research, 2013, 19, 6624-6632.	7.0	32
60	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 2012, 30, 3452-3459.	1.6	824
61	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature, 2012, 490, 116-120.	27.8	759
62	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature, 2011, 476, 298-303.	27.8	1,428
63	Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica, 2010, 95, 597-603.	3.5	87
64	Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Laboratory Investigation, 2007, 87, 979-997.	3.7	50
65	Molecular Diagnosis of Burkitt's Lymphoma. New England Journal of Medicine, 2006, 354, 2431-2442.	27.0	824
66	Benign B-Cell Precursors (Hematogones) Are the Predominant Lymphoid Population in the Bone Marrow of Preterm Infants. Neonatology, 2004, 86, 247-253.	2.0	13
67	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood, 2004, 103, 4251-4258.	1.4	296